BACKGROUND: Our goal was to investigate de novo purine biosynthetic gene PAICS expression and evaluate its role in prostate cancer progression. METHODS: Next-generation sequencing, qRTPCR and immunoblot analysis revealed an elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a progressive manner in prostate cancer. Functional analyses were performed using prostate cancer cell lines- DU145, PC3, LnCaP, and VCaP. The oncogenic properties of PAICS were studied both by transient and stable knockdown strategies, in vivo chicken chorioallantoic membrane (CAM) and murine xenograft models. Effect of BET bromodomain inhibitor JQ1 on the expression level of PAICS was also studied. RESULTS: Molecular staging of prostate cancer is important factor in effective diagnosis, prognosis and therapy. In this study, we identified a de novo purine biosynthetic gene; PAICS is overexpressed in PCa and its expression correlated with disease aggressiveness. Through several in vitro and in vivo functional studies, we show that PAICS is necessary for proliferation and invasion in prostate cancer cells. We identified JQ1, a BET bromodomain inhibitor previously implicated in regulating MYC expression and demonstrated role in prostate cancer, abrogates PAICS expression in several prostate cancer cells. Furthermore, we observe loss of MYC occupancy on PAICS promoter in presence of JQ1. CONCLUSIONS: Here, we report that evaluation of PAICS in prostate cancer progression and its role in prostate cancer cell proliferation and invasion and suggest it as a valid therapeutic target. We suggest JQ1, a BET-domain inhibitor, as possible therapeutic option in targeting PAICS in prostate cancer. Prostate 77:10-21, 2017.
BACKGROUND: Our goal was to investigate de novo purine biosynthetic gene PAICS expression and evaluate its role in prostate cancer progression. METHODS: Next-generation sequencing, qRTPCR and immunoblot analysis revealed an elevated expression of a de novo purine biosynthetic gene, Phosphoribosylaminoimidazole Carboxylase, Phosphoribosylaminoimidazole Succinocarboxamide Synthetase (PAICS) in a progressive manner in prostate cancer. Functional analyses were performed using prostate cancer cell lines- DU145, PC3, LnCaP, and VCaP. The oncogenic properties of PAICS were studied both by transient and stable knockdown strategies, in vivo chicken chorioallantoic membrane (CAM) and murine xenograft models. Effect of BET bromodomain inhibitor JQ1 on the expression level of PAICS was also studied. RESULTS: Molecular staging of prostate cancer is important factor in effective diagnosis, prognosis and therapy. In this study, we identified a de novo purine biosynthetic gene; PAICS is overexpressed in PCa and its expression correlated with disease aggressiveness. Through several in vitro and in vivo functional studies, we show that PAICS is necessary for proliferation and invasion in prostate cancer cells. We identified JQ1, a BET bromodomain inhibitor previously implicated in regulating MYC expression and demonstrated role in prostate cancer, abrogates PAICS expression in several prostate cancer cells. Furthermore, we observe loss of MYC occupancy on PAICS promoter in presence of JQ1. CONCLUSIONS: Here, we report that evaluation of PAICS in prostate cancer progression and its role in prostate cancer cell proliferation and invasion and suggest it as a valid therapeutic target. We suggest JQ1, a BET-domain inhibitor, as possible therapeutic option in targeting PAICS in prostate cancer. Prostate 77:10-21, 2017.
Authors: Balabhadrapatruni V S K Chakravarthi; Darshan S Chandrashekar; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Satya S Pathi; Moloy T Goswami; Xiaojun Jing; Rui Wang; Rohit Mehra; Irfan A Asangani; Arul M Chinnaiyan; Upender Manne; Guru Sonpavde; George J Netto; Jennifer Gordetsky; Sooryanarayana Varambally Journal: Mol Cancer Res Date: 2017-10-12 Impact factor: 5.852
Authors: Sumit Agarwal; Balabhadrapatruni V S K Chakravarthi; Hyung-Gyoon Kim; Nirzari Gupta; Kevin Hale; Sai Akshaya Hodigere Balasubramanya; Patsy G Oliver; Dafydd G Thomas; Isam-Eldin A Eltoum; Donald J Buchsbaum; Upender Manne; Sooryanarayana Varambally Journal: Transl Oncol Date: 2020-05-15 Impact factor: 4.243
Authors: Lucie Mádrová; Matyáš Krijt; Veronika Barešová; Jan Václavík; David Friedecký; Dana Dobešová; Olga Součková; Václava Škopová; Tomáš Adam; Marie Zikánová Journal: PLoS One Date: 2018-12-10 Impact factor: 3.240
Authors: Balabhadrapatruni V S K Chakravarthi; Maria Del Carmen Rodriguez Pena; Sumit Agarwal; Darshan S Chandrashekar; Sai Akshaya Hodigere Balasubramanya; Fayez J Jabboure; Andres Matoso; Trinity J Bivalacqua; Katayoon Rezaei; Alcides Chaux; William E Grizzle; Guru Sonpavde; Jennifer Gordetsky; George J Netto; Sooryanarayana Varambally Journal: Neoplasia Date: 2018-08-15 Impact factor: 5.715
Authors: Caroline K Søgaard; Siver A Moestue; Morten B Rye; Jana Kim; Anala Nepal; Nina-Beate Liabakk; Siri Bachke; Tone F Bathen; Marit Otterlei; Deborah K Hill Journal: Oncotarget Date: 2018-01-27
Authors: Sumit Agarwal; Balabhadrapatruni V S K Chakravarthi; Michael Behring; Hyung-Gyoon Kim; Darshan S Chandrashekar; Nirzari Gupta; Prachi Bajpai; Amr Elkholy; Sai A H Balasubramanya; Cherlene Hardy; Sameer Al Diffalha; Sooryanarayana Varambally; Upender Manne Journal: Cancers (Basel) Date: 2020-03-25 Impact factor: 6.639